Netscientific PLC (LON:NSCI) announced that its US-based portfolio company, Vortex BioSciences, a leading liquid biopsy company, is to present "compelling new data" at the American Association for Cancer Research (AACR) Annual Meeting bring held in Chicago from 14 April to 18 April 2018.
The transatlantic healthcare IP commercialisation group said the studies support the use of Vortex's non-invasive technology in the characterisation of circulating tumour cells (CTCs) for important clinical biomarkers, namely EGFR and PD-L1.
The firm said these biomarkers play a pivotal role in the development and progression of certain cancer in patients with non-small cell lung cancer (NSCLC).
Commenting on the news, Francois Martelet, Vortex BioSciences’ chairman and CEO of NetScientific said: "The studies presented underscore the potential use of Vortex's technology in the diagnosis and treatment of cancer patients.
“It is paramount to understand which patients are likely to exhibit a superior response to targeted therapies in order to determine the best treatment algorithm, as well as to contain healthcare expenditure.
“We firmly believe that Vortex's technology can play an instrumental role in this."